Solriamfetol hydrochloride (JZP-110 hydrochloride) 是一种口服有效的，选择性的多巴胺和去甲肾上腺素再摄取抑制剂，对多巴胺和去甲肾上腺素转运蛋白的 IC50 分别为 2.9 μM 和 4.4 μM。Solriamfetol hydrochloride 具有强大的促唤醒作用。
Solriamfetol hydrochloride (JZP-110 hydrochloride) is an orally active and selective dopamine and norepinephrine reuptake inhibitor with IC50s of 2.9 μM and 4.4 μM for dopamine and norepinephrine transporters, respectively. Solriamfetol hydrochloride has robust wake-promoting effects[1][2].
[1]. Baladi MG, et al. Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor. J Pharmacol Exp Ther. 2018 Aug;366(2):367-376. [2]. Yang J, et al. Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy. Expert Rev Clin Pharmacol. 2019 Aug;12(8):723-728.
动态评分
0.0